Daiichi Sankyo creates new biz unit for oncology
Singapore, Nov. 13 -- Japanese firm Daiichi Sankyo Company has announced that it will create a new Oncology Business Unit, effective April 1, 2021, aligning the US and European oncology businesses, global oncology functions of marketing, market access and pricing, medical affairs as well as alliance management under one team singularly devoted to people with cancer.
Ken Keller, currently leading the US Business and CEO of the Company's US affiliates Daiichi Sankyo, Inc and American Regent, Inc, will lead this new team as Head of the Oncology Business Unit, effective, April 1, 2021, and will remain President and CEO of Daiichi Sankyo, Inc. Paul Diolosa, currently Senior Vice President of Operations of American Regent, Inc, will succeed Ke...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.